Biography for Eric Sagonowsky
Eric Sagonowsky, Associate Editor
Eric Sagonowsky is an associate editor with the FierceMarkets Life Sciences team. Before joining Fierce in November 2014, Eric worked as a news reporter for the Manistee News Advocate in Manistee, Mich., covering government and crime issues. Eric graduated from Ohio University's E.W. Scripps School of Journalism in 2012 with a degree in Online Journalism. On campus, Eric wrote for The Athens News and The New Political. In his free time, Eric enjoys outdoor recreation, following sports of all kinds and exploring the metro D.C. area. He can be reached at email@example.com. Follow @EricSFierce on Twitter.
Articles by Eric Sagonowsky
Months after its formation last fall, CSL's flu vaccines unit Seqirus is a loss-making entity. However, leadership there believes the operation can achieve "industry leadership" in 5 to 10 years by relying on a move into quadrivalent vaccines, the launch of Fluad and emerging markets growth.
As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.
Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.
Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.
A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.
Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.
A vaccine developed in collaboration between GlaxoSmithKline and the U.S. Army failed to protect subjects in an early trial against the world's most prevalent malaria parasite. Researchers will press forward, however, saying the knowledge gained may assist future development.
Seqirus--the world's second largest flu vaccine player formed CSL's purchase of Novartis flu vaccines--this week said it's expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there.
Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.
Brazil officials signed off this week on funding for a late-stage dengue vaccine trial, adding another twist to the global dengue vaccine competition amid the launch of the first approved jab.